Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2720-2728

  Menne, Stephan ^a   Cote, Paul J ^b   Korba, Brent E ^b   Butler, Scott D ^a   George, Andrea L ^a   Tochkov, Ilia A ^a   Delaney IV, William E ^c   Xiong, Shelly ^c   Gerin, John L ^b   Tennant, Bud C ^a  

^a Department of Obstetrics Gynecology   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS; HEPATITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION; WOODCHUCK;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; MARMOTA; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

EID: 21444441074     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2720-2728.2005     Document Type: Article

References (55)

1. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A, Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
2. Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-2739.
3. Benhamou, Y., R. Tubiana, and V. Thibault. 2003. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N. Engl. J. Med. 348:177-178.
4. Bessesen, M., D. Ives, L. Condreay, S. Lawrence, and K. E. Sherman. 1999. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin. Infect. Dis. 28:1032-1035.
5. Bruno, R., P. Sacchi, C. Zocchetti, V. Ciappina, M. Puoti, and G. Filice. 2003. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 17:783-784.
6. Bryant, M. L., E. G. Bridges, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernandez, A. Juodawlkis, B. Tenmint, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R. F. Schinazi, and J. P. Sommadossi. 2001. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:229-235.
7. Carreno, V., J. C. Porres, I. Mora, J. Gutiez, J. A. Quiroga, S. Ramon y Cajal, H. Oliva, C. Compernolle, and J. Bartolome. 1987. A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules. Antivir. Res. 8:125-137.
8. Colonno, R. J., E. V. Genovesi, I. Medina, L. Lamb, S. K. Durham, M. L. Huang, L. Corey, M. Littlejohn, S. Locarnini, B. C. Tennant, B. Rose, and J. M. Clark. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184:1236-1245.
9. Cote, P. J., B. E. Korba, R. H. Miller, J. R. Jacob, B. H. Baldwin, W. E. Hornbuckle, R. H. Purcell, B. C. Tennant, and J. L. Gerin. 2000. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 31:190-200.
10. Cote, P. J., C. Roneker, K. Cass, F. Schodel, D. Peterson, B. Tennant, F. De Noronha, and J. Gerin. 1993. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol. 6:161-169.
11. Cote, P. J., I. Toshkov, I. Nakamura, S. Menne, B. Korba, B. Tennant, and J. Gerin. 2002. Chronicity as an outcome of experimental neonatal wood-chuck hepatitis virus infection results from a deficient type 1 immune response to acute infection, p. 280-285. In H. S. Margolis, M. J. Alter, T. J. Liang, and J. L. Dienstag (ed.), Viral hepatitis and liver diseases. Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. International Medical Press Ltd., Atlanta, Ga.
12. Cullen, J. M., D. H. Li, C. Brown, E. J. Eisenberg, K. C. Cundy, J. Wolfe, J. Toole, and C. Gibbs. 2001. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected wood-chucks. Antimicrob. Agents Chemother. 45:2740-2745.
13. Cullen, J. M., S. L. Smith, M. G. Davis, S. E. Dunn, C. Botteron, A. Cecchi, D. Linsey, D. Linzey, L. Frick, M. T. Paff, A. Goulding, and K. Biron. 1997. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 41:2076-2082.
14. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. O. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(A)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
15. Delaugerre, C., A. G. Marcelin, V. Thibault, G. Peytavin, T. Bombled, M. V. Bochet, C. Katlama, Y. Benhamou, and V. Calvez. 2002. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob. Agents Chemother. 46:1586-1588.
16. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
17. Dore, G. J., D. A. Cooper, A. L. Pozniak, E. DeJesus, L. Zhong, M. D. Miller, B. Lu, and A. K. Cheng. 2004. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189:1185-1192.
18. Ganem, D. 1996. Hepadnaviridae: the viruses and their replication, p. 2703-2737. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
19. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
20. Hoff, J., F. Bani-Sadr, M. Gassin, and F. Raffi. 2001. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin. Infect. Dis. 32:963-969.
21. Hostetler, K. Y., J. R. Beadle, W. E. Hornbuckle, C. A. Bellezza, I. A. Tochkov, P. J. Cote, J. L. Gerin, B. E. Korba, and B. C. Tennant. 2000. Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob. Agents Chemother. 44:1964-1969.
22. Hussain, M., and A. S. Lok. 1999. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J. Viral Hepat. 6:183-194.
23. Jacob, J. R., B. E. Korba, P. J. Cote, I. Toshkov, W. E. Delaney IV, J. L. Gerin, and B. C. Tennant. 2004. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antivir. Res. 63:115-121.
24. Kiriakidis, M. 2001. The determination of GS-1278 (R-PMPA) in rhesus monkey plasma (EDTA) using a high performance liquid Chromatographic mass spectrometric method. MDS Pharma Services, Montreal, Canada.
25. Korba, B. E., P. Cote, W. Hornbuckle, R. Schinazi, J. D. Gangemi, B. C. Tennant, and J. L. Gerin. 2000. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir. Ther. 5:95-104.
26. Korba, B. E., P. Cote, W. Hornbuckle, R. Schinazi, J. L. Gerin, and B. C. Tennant. 2000. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antivir. Res. 45:19-32.
27. Korba, B. E., P. Cote, W. Hornbuckle, B. C. Tennant, and J. L. Gerin. 2000. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175.
28. Korba, B. E., R. F. Schinazi, P. Cote, B. C. Tennant, and J. L. Gerin. 2000. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 44:1757-1760.
29. Kuo, A., J. L. Dienstag, and R. T. Chung. 2004. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin. Gastroenterol. Hepatol. 2:266-272.
30. Lau, D. T., M. F. Khokhar, E. Doo, M. G. Ghany, D. Herion, Y. Park, D. E. Kleiner, P. Schmid, L. D. Condreay, J. Gauthier, M. C. Kuhns, T. J. Liang, and J. H. Hoofnagle. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
31. Louie, M., C. Hogan, A. Hurley, V. Simon, C. Chung, N. Padte, P. Lamy, J. Flaherty, D. Coakley, M. Di Mascio, A. S. Perelson, and M. Markowitz. 2003. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17:1151-1156.
32. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B E antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
33. Menne, S., and P. J. Cote. 2003. The woodchuck as an emerging animal model for immunopathogenesis and immunotherapy of human HBV infection. Recent Res. Dev. Virol. 5:117-141.
34. Menne, S., C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant, and P. J. Cote. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 76:5305-5314.
35. Menne, S., and B. C. Tennant. 1999. Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat. Med. 5:1125-1126.
36. Nelson, M., S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, G. Matthews, D. Pillay, M. Fisher, M. Bower, and B. Gazzard. 2003. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 17:F7-F10.
37. Nunez, M., M. Perez-Olmeda, B. Diaz, P. Rios, J. Gonzalez-Lahoz, and V. Soriano. 2002. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 16:2352-2354.
38. Peek, S. F., P. J. Cote, J. R. Jacob, I. A. Toshkov, W. E. Hornbuckle, B. H. Baldwin, F. V. Wells, C. K. Chu, J. L. Gerin, B. C. Tennant, and B. E. Korba. 2001. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl- beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254-266.
39. Perrillo, R., E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, K. Gutfreund, P. Lamy, and A. Murray. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134.
40. Renault, P. F., and J. H. Hoofnagle. 1989. Side effects of alpha interferon. Semin. Liver Dis. 9:273-277.
41. Ristig, M. B., J. Crippin, J. A. Aberg, W. G. Powderly, M. Lisker-Melman, L. Kessels, and P. Tebas. 2002. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J. Infect. Dis. 186:1844-1847.
42. Tennant, B. C., B. H. Baldwin, L. A. Graham, M. A. Ascenzi, W. E. Hornbuckle, P. H. Rowland, I. A. Tochkov, A. E. Yeager, H. N. Erb, J. M. Colacino, C. Lopez, J. A. Engelhardt, R. R. Bowsher, F. C. Richardson, W. Lewis, P. J. Cote, B. E. Korba, and J. L. Gerin. 1998. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28:179-191.
43. Tennant, B. C., I. A. Toshkov, S. F. Peek, J. R. Jacob, S. Menne, W. E. Hornbuckle, R. D. Schinazi, B. E. Korba, P. J. Cote, and J. L. Gerin. 2004. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127(Suppl. 1):S283-S293.
44. Thibault, V., Y. Benhamou, C. Seguret, M. Hochet, C. Katlama, F. Bricaire, P. Opolon, T. Poynard, and H. Agut. 1999. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J. Clin. Microbiol. 37:3013-3016.
45. Van Bommel, F., A. Schernick, U. Hopf, and T. Berg. 2003. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 124:586-587.
46. Van Bommel, F., T. Wunsche, S. Mauss, P. Reinke, A. Bergk, D. Schurmann, B. Wiedenmann, and T. Berg. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40:1421-1425.
47. Van Bommel, F., T. Wunsche, D. Schurmann, and T. Berg. 2002. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36:507-508.
48. Villeneuve, J. P., D. Durantel, S. Durantel, C. Westland, S. Xiong, C. L. Brosgart, C. S. Gibbs, P. Parvaz, B. Werle, C. Trepo, and F. Zoulim. 2003. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39:1085-1089.
49. Vryheid, R. E., M. A. Kane, N. Muller, G. C. Schatz, and S. Bezabehd. 2000. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 19:1026-1037.
50. Westland, C. E., H. Yang, W. E. Delaney IV, C. S. Gibbs, M. D. Miller, M. Wulfsohn, J. Fry, C. L. Brosgart, and S. Xiong. 2003. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38:96-103.
51. Xiong, S., H. Yang, C. E. Westland, W. E. Delaney, D. Colledge, A. Bartholomeusz, V. Thibault, Y. Benhamou, P. Angus, M. Wulfsohn, C. S. Gibbs, J. Fry, C. L. Brosgart, and S. Locarnini. 2003. Resistance surveillance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). J. Hepatol. 38(Suppl. 2):182.
52. Yang, H., C. E. Westland, W. E. Delaney IV, E. J. Heathcote, V. Ho, J. Fry, C. Brosgart, C. S. Gibbs, M. D. Miller, and S. Xiong. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36:464-473.
53. Ying, C., E. De Clercq, and J. Neyts. 2000. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J. Viral Hepat. 7:79-83.
54. Ying, C., E. De Clercq, W. Nicholson, P. Furman, and J. Neyts. 2000. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral Hepat. 7:161-165.
55. Yokota, T., K. Konno, E. Chonan, S. Mochizuki, K. Kojima, S. Shigeta, and E. de Clercq. 1990. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother. 34:1326-1330.